Impact of first-line combination treatment on outcomes of second-line TKI in advanced kidney cancer
There is limited information on the outcomes of patients who [...]
Cabozantinib most promising for refractory metastatic kidney cancer
In a European study of second-line treatments for metastatic kidney [...]
First CAR T-cell therapy for kidney cancer given Advanced Therapy designation by the FDA
The US Food and Drug Administration (FDA) has granted a [...]
Comparison of cabozantinib with axitinib as second-line treatment for metastatic kidney cancer
To date, there have not been any studies that have [...]
Lenvatinib plus everolimus for patients with metastatic kidney cancer
The treatment of heavily pretreated patients with metastatic kidney cancer [...]
Real world data on the use of cabozantinib plus immunotherapy in the second line
A recent study looked at the use of a combination [...]
METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
FDA approves belzutifan for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Belzutifan plus cabozantinib combination shows promising results in kidney cancer
Kidney cancers often have mutations in a gene called the [...]
